Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Income from Continuing Operations for 2 consecutive years, with 1864092.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 195.92% to 1864092.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6132335.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 838059.0 for FY2025, 93.87% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 1864092.0 at Neuphoria Therapeutics, up from 9906504.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 11262161.0 in Q1 2025, with the low at 9906504.0 in Q3 2025.